[go: up one dir, main page]

CL2008001202A1 - Peptido scfv que comprende un dominio vh y un dominio vl enlazados por un espaciador de aminocidos; molecula de acido nucleico que comprende el peptido antes mencionado;composicion farmaceutica que comprende dicho peptido. - Google Patents

Peptido scfv que comprende un dominio vh y un dominio vl enlazados por un espaciador de aminocidos; molecula de acido nucleico que comprende el peptido antes mencionado;composicion farmaceutica que comprende dicho peptido.

Info

Publication number
CL2008001202A1
CL2008001202A1 CL2008001202A CL2008001202A CL2008001202A1 CL 2008001202 A1 CL2008001202 A1 CL 2008001202A1 CL 2008001202 A CL2008001202 A CL 2008001202A CL 2008001202 A CL2008001202 A CL 2008001202A CL 2008001202 A1 CL2008001202 A1 CL 2008001202A1
Authority
CL
Chile
Prior art keywords
peptide
domain
pharmaceutical composition
amino acid
nucleic acid
Prior art date
Application number
CL2008001202A
Other languages
English (en)
Inventor
James Y Wechner Philipp Burnie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008001202A1 publication Critical patent/CL2008001202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Péptido scfv que comprende un dominio Vh y un dominio Vl enlazados por un espaciador de aminoácidos; molécula de ácido nucleico que comprende el péptido antes mencionado; composición farmacéutica que comprende dicho péptido.
CL2008001202A 2007-04-27 2008-04-25 Peptido scfv que comprende un dominio vh y un dominio vl enlazados por un espaciador de aminocidos; molecula de acido nucleico que comprende el peptido antes mencionado;composicion farmaceutica que comprende dicho peptido. CL2008001202A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07107140 2007-04-27
EP07113353 2007-07-27

Publications (1)

Publication Number Publication Date
CL2008001202A1 true CL2008001202A1 (es) 2008-12-19

Family

ID=39717534

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001202A CL2008001202A1 (es) 2007-04-27 2008-04-25 Peptido scfv que comprende un dominio vh y un dominio vl enlazados por un espaciador de aminocidos; molecula de acido nucleico que comprende el peptido antes mencionado;composicion farmaceutica que comprende dicho peptido.

Country Status (21)

Country Link
US (3) US20100113355A1 (es)
EP (2) EP2152746A1 (es)
JP (1) JP2010524485A (es)
KR (1) KR20100017387A (es)
CN (1) CN101679517A (es)
AR (1) AR066311A1 (es)
AU (1) AU2008244308A1 (es)
BR (1) BRPI0810827A2 (es)
CA (1) CA2685136A1 (es)
CL (1) CL2008001202A1 (es)
CR (1) CR11059A (es)
EA (1) EA200901441A1 (es)
EC (1) ECSP099765A (es)
GT (1) GT200900276A (es)
IL (1) IL201445A0 (es)
MA (1) MA31384B1 (es)
MX (1) MX2009011595A (es)
PE (1) PE20090728A1 (es)
TN (1) TN2009000442A1 (es)
TW (1) TW200902714A (es)
WO (2) WO2008132134A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
EP3783034A1 (en) * 2014-07-23 2021-02-24 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72)
CN105652011B (zh) * 2014-11-20 2017-09-22 深圳市安群生物工程有限公司 检测人HSP90α‑2蛋白的荧光免疫层析试纸及其制备方法
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732852A (en) 1981-11-20 1988-03-22 Cetus Corporation Site directed peptidase cleavage
US4670382A (en) 1983-12-02 1987-06-02 Temple University--of the Commonwealth System of Higher Education Monoclonal antibody to Candida albicans cytoplasmic antigens and methods of preparing same
US4806465A (en) 1984-01-16 1989-02-21 Temple University Of The Commonwealth System Of Higher Education Cytoplasmic antigens of candida albicans and methods of using the same
GB8506373D0 (en) 1985-03-12 1985-04-11 Axon Healthcare Ltd Antigens antibodies
GB8915019D0 (en) 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
AU769235B2 (en) 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
ES2287044T3 (es) 2000-01-25 2007-12-16 Oklahoma Medical Research Foundation Procedimiento universal para el replegamiento de proteinas recombinantes.
GB0008305D0 (en) 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections
WO2002006990A1 (en) 2000-07-14 2002-01-24 Healthcite, Inc. Method and system for providing medical information
AU2002252179A1 (en) 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
GB0127983D0 (en) 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0409077D0 (en) * 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
CN101010100A (zh) 2004-07-02 2007-08-01 纽泰克医药有限公司 癌症的治疗方法
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (en) 2007-04-27 2008-11-06 Novartis Ag An immunoglobulin composition

Also Published As

Publication number Publication date
WO2008132152A1 (en) 2008-11-06
MA31384B1 (fr) 2010-05-03
EP2152746A1 (en) 2010-02-17
TN2009000442A1 (en) 2011-03-31
ECSP099765A (es) 2009-12-28
CN101679517A (zh) 2010-03-24
MX2009011595A (es) 2009-12-08
AU2008244308A1 (en) 2008-11-06
PE20090728A1 (es) 2009-07-02
WO2008132134A9 (en) 2009-07-09
US20090136484A1 (en) 2009-05-28
EA200901441A1 (ru) 2010-04-30
EP2144932A1 (en) 2010-01-20
CA2685136A1 (en) 2008-11-06
IL201445A0 (en) 2010-06-16
WO2008132134A1 (en) 2008-11-06
GT200900276A (es) 2010-05-21
US7722869B2 (en) 2010-05-25
JP2010524485A (ja) 2010-07-22
AR066311A1 (es) 2009-08-12
KR20100017387A (ko) 2010-02-16
US20100166758A1 (en) 2010-07-01
BRPI0810827A2 (pt) 2014-10-29
US20100113355A1 (en) 2010-05-06
CR11059A (es) 2009-11-20
TW200902714A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
CL2008001202A1 (es) Peptido scfv que comprende un dominio vh y un dominio vl enlazados por un espaciador de aminocidos; molecula de acido nucleico que comprende el peptido antes mencionado;composicion farmaceutica que comprende dicho peptido.
DK2719388T3 (da) Borholdige små molekyler som antiinflammatoriske midler
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0812400A2 (pt) Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
BRPI0719393A2 (pt) Composição farmacêutica
EP3450425C0 (en) PERCARBOXYLIC ACID COMPOSITION
EP2191826A4 (en) PHARMACEUTICAL COMPOSITION
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
DE602007012648D1 (de) Härtbare Zusammensetzung
DE602007004820D1 (de) Härtbare Zusammensetzung
BRPI0910288A2 (pt) composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo.
BRPI0921717A2 (pt) composto, sequência de peptídeo isolada, composição farmacêutica, uso de um composto, anticorpo, e, método de tratamento
BRPI0810399A2 (pt) Composto, composição farmacêutica que o contém e uso do mesmo
EP2116241A4 (en) PHARMACEUTICAL COMPOSITION
BRPI0821197A2 (pt) Composto, composição farmacêutica, uso de um composto, processo, e, intermediário.
EP2224806A4 (en) PHARMACEUTICAL COMPOSITION
BRPI0810009A2 (pt) Composto, composição farmacêutica, e, intermediário sintético
FI20086014A0 (fi) Nukleiinihappoja sitova peptidi
UA13130S (uk) Етикетка для майонезу
UA14730S (uk) Етикетка для майонезу
BRPI0719398A2 (pt) Composição farmacêutica.
UA13304S (uk) Комплект етикеток до пляшки
UA13785S (uk) Комплект етикеток до пляшки
UA13792S (uk) Комплект етикеток до пляшки